Search results for "Chronic obstructive"

showing 10 items of 321 documents

Comment to the Editorial by KS Park and EW Kang “Is only fixed positive airway pressure a robust tool for kidney protection in patients with obstruct…

2019

We thank doctors Park and Kang for their editorial that well summarized our article. Our common belief is that one of the possible consequences of untreated obstructive sleep apnea (OSA) is an accelerated deterioration of kidney function, and that more knowledge would be necessary on the possible protective effects of OSA treatments. To our knowledge, so far the only OSA therapy whose effects on renal function have been tested is continuous positive airway pressure (CPAP), and most , although not all studies, have demonstrated its benefits. Our own study, while confirming benefits of fixed CPAP, has demonstrated little effect of auto-adjusting CPAP (APAP). This finding may be of relevance a…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyLetterestimated glomerular filtration ratekidney diseaseRenal functionPolysomnographySettore MED/10 - Malattie Dell'Apparato Respiratoriosleep disordered breathingpolysomnographyrenal protectionPositive airway pressureMedicineIn patienthumansleepIntensive care medicinekidney functionLetter to the EditorPositive end-expiratory pressureKidneymedicine.diagnostic_testbusiness.industryobstructive sleep apnea ; kidney protection ; fixed positive airway pressuremedicine.diseaseoxygen saturationrespiratory tract diseasesObstructive sleep apneaNot availablemedicine.anatomical_structureEditorialpositive end expiratory pressureHuman medicinebusinesschronic obstructive lung diseaseKidney disease
researchProduct

Eligibility of real-life patients with copd for inclusion in rcts: A commentary

2017

Randomized clinical trials (RCTs) are performed to provide evidence to support treatment decisions. Based on the nature of those studies and the need to avoid confounding factors, it has been argued that the population selected in RCTs only partially represents the real-life population. This assumption casts doubts on the applicability of the results provided by RCTs in the management of individuals with an established diagnosis of COPD, and advocates the need for complementary studies with a pragmatic design. Herein, we comment on the recent article published by Halpin and colleagues on the Journal [Halpin et al, Respir Res 17:120, 2016], in which higher rates of inclusions in RCTs for COP…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPediatricsInclusion (disability rights)PopulationAlternative medicineEligibility DeterminationCOPD researchClinical practiceSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionPulmonary Disease Chronic Obstructive03 medical and health sciencesClinical trials0302 clinical medicineRandomized controlled triallawHumansMedicine030212 general & internal medicineEligibility DeterminationIntensive care medicineeducationRandomized Controlled Trials as TopicCOPDeducation.field_of_studybusiness.industryPatient SelectionConfoundingmedicine.diseaseClinical trialClinical trial030228 respiratory systemCommentaryClinical practice; Clinical trials; COPD research; Pulmonary and Respiratory Medicinebusiness
researchProduct

Moving from the Oslerian paradigm to the postgenomic era: Are asthma and COPD outdated terms?

2016

In the majority of cases, asthma and chronic obstructive pulmonary disease (COPD) are two clearly distinct disease entities. However, in some patients there may be significant overlap between the two conditions. This constitutes an important area of concern because these patients are generally excluded from randomised controlled trials (mostly because of smoking history in the case of asthma or because of significant bronchodilator reversibility in the case of COPD). As a result, their pathobiology, prognosis and response to therapy are largely unknown. This may lead to suboptimal management and can limit the development of more personalised therapeutic options. Emerging genetic and molecul…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPlacebo-controlled studyAlternative medicinePHENOTYPESAIRWAY DISEASEDiseasePLACEBO-CONTROLLED TRIALOBSTRUCTIVE PULMONARY-DISEASETHERAPYCOPD MechanismsDOUBLE-BLINDPulmonary Disease Chronic ObstructiveAsthma; COPD MechanismsTerminology as TopicmedicineHumansDiseasePrecision MedicineIntensive care medicineINDEXAsthmaCLUSTER-ANALYSISCOPDbusiness.industrySystems Biologymedicine.diseaseAsthmaLUNG-FUNCTIONSystems medicineEXACERBATIONSPhenotypePhysical therapyHealth educationPersonalized medicinebusinessThorax
researchProduct

Should we use gait speed in COPD, FEV 1 in frailty and dyspnoea in both?

2016

Frailty is a progressive physiological decline in multiple organ systems marked by loss of function, loss of physiological reserve and increased vulnerability to disease [1]. Biological (inflammation and loss of hormones), clinical ( e.g. sarcopenia and osteoporosis) and social factors are involved in frailty onset, evolution and prognosis [2, 3]. Links between frailty, dyspnoea and chronic respiratory diseases represent a novel and practical approach

Pulmonary and Respiratory Medicinemedicine.medical_specialty[SDV]Life Sciences [q-bio]OsteoporosisDiseaseIdoso FragilizadoDispneia03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineInternal medicineForced Expiratory VolumemedicineHumans030212 general & internal medicineLoss functionOrgan systemComputingMilieux_MISCELLANEOUSAgedAged 80 and overCOPDFrailtybusiness.industrymedicine.disease3. Good healthGait speedWalking SpeedPreferred walking speedDyspnea030228 respiratory systemSarcopeniaPhysical therapyCardiologyDoença Pulmonar Obstrutiva CrónicaVolume Expiratório ForçadoAged; Aged 80 and over; Dyspnea; Forced Expiratory Volume; Frailty; Humans; Pulmonary Disease Chronic Obstructive; Walking Speed; Pulmonary and Respiratory MedicinebusinessHuman
researchProduct

The Contribution of Small-Airway Abnormalities in Chronic Obstructive Pulmonary Disease Clinical Manifestations: More than a Functional Issue.

2016

Pulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industryMEDLINESocio-culturalePulmonary diseaseSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineText mining030228 respiratory systemAirway abnormalitiesmedicineHumans030212 general & internal medicineIntensive care medicinebusinessHumanRespiration; international review of thoracic diseases
researchProduct

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD

2020

This exploratory, randomised, double-blind, double-dummy, multicentre, cross-over study explored the effect of 6 weeks of treatment with tiotropium/olodaterol (T/O) versus fluticasone propionate/salmeterol (F/S) on left ventricular filling in patients with chronic obstructive pulmonary disease with functional residual capacity (FRC) >120% predicted and postbronchodilator improvement of FRC ≥7.5%. Overall, 76 patients were randomised across nine sites. Treatment with T/O or F/S increased left ventricular end-diastolic volume index from baseline (adjusted mean change: T/O: 2.317 mL/m2, F/S: 2.855 mL/m2), with no statistically significant difference between treatments. However, T/O resulted…

Pulmonary and Respiratory Medicinemedicine.medical_specialtylcsh:MedicineFluticasone propionatePulmonary Disease Chronic Obstructive03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFunctional residual capacityInternal medicinemedicineHumansMulticenter Studies as TopicPlethysmographIn patient1506030212 general & internal medicineTiotropium BromideLunginhaler devicesRandomized Controlled Trials as Topiclcsh:RC705-779COPDCross-Over Studiesbusiness.industrylcsh:ROlodaterollcsh:Diseases of the respiratory systemrespiratory systemmedicine.diseaseFluticasone-Salmeterol Drug CombinationBenzoxazinesBronchodilator Agentsrespiratory tract diseasesrespiratory measurement030228 respiratory systemchemistryPerspectiveCardiologyCOPD pharmacologySalmeterolVentricular fillingbusinessmedicine.drugBMJ Open Respiratory Research
researchProduct

The use of bronchodilators in the treatment of airway obstruction in elderly patients

2006

Abstract Ageing is associated with important anatomical, physiological and psychosocial changes that may have an impact on the management of obstructive airway diseases (asthma and chronic obstructive pulmonary disease (COPD)) and on their optimal therapy. Ageing-related modifications might be responsible for a different effectiveness of bronchodilators in the elderly patients as compared to younger subjects. Furthermore, the physiological involution of organs and the frequent comorbidity, often interfere with pharmacokinetics of bronchodilator drugs used in asthma and COPD. This review will focus on the use of bronchodilators in the elderly, with particular attention to the achievable goal…

Pulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classSettore MED/10 - Malattie Dell'Apparato RespiratorioCholinergic AntagonistsPulmonary Disease Chronic ObstructiveElderlyBronchodilatorasthma COPDmedicineHumansPharmacology (medical)Intensive care medicineAdverse effectAsthmaAgedCOPDbusiness.industryBiochemistry (medical)Airway obstructionAdrenergic beta-Agonistsmedicine.diseaseComorbidityrespiratory tract diseasesBronchodilator AgentsbronchodilatorsAirway ObstructionBronchodilator AgentsXanthinesAirwaybusiness
researchProduct

Withdrawal of inhaled corticosteroids in COPD: A meta-analysis

2017

Background Conflicting findings exist on the benefit of withdrawal of inhaled corticosteroid (ICS) in chronic obstructive pulmonary disease (COPD). We performed a quantitative synthesis in order to assess real impact of ICS discontinuation in COPD patients. Methods We carried out a meta-analysis via random-effects model on the available clinical evidence to evaluate the effect of ICS discontinuation in COPD. Randomized clinical trials and observational real-life studies investigating the effects of ICS withdrawal on the risk of COPD exacerbation, lung function (forced expiratory volume in 1 s [FEV1]) and quality of life (St. George's Respiratory Questionnaire [SGRQ]) were identified by sear…

Pulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classSocio-culturaleSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.invention03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineGlucocorticoidQuality of lifeRandomized controlled triallawInhaled corticosteroidForced Expiratory VolumeAdministration InhalationmedicineHumansPharmacology (medical)030212 general & internal medicineIntensive care medicineGlucocorticoidsRandomized Controlled Trials as TopicRespiratory Function TestCOPDInhaled corticosteroidsbusiness.industryChronic obstructive pulmonary diseaseBiochemistry (medical)medicine.diseaseRespiratory Function TestsDiscontinuationrespiratory tract diseasesChronic obstructive pulmonary disease; Inhaled corticosteroids; Withdrawal030228 respiratory systemWithholding TreatmentMeta-analysisRelative riskWithdrawalQuality of LifeCorticosteroidObservational studyChronic obstructive pulmonary disease; Inhaled corticosteroids; Withdrawal; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)businessHuman
researchProduct

Frailty Assessment in a Stable COPD Cohort: Is There a COPD-Frail Phenotype?

2021

The frailty syndrome increases the morbidity/mortality in older adults, and several studies have shown a higher prevalence of this syndrome in patients with Chronic Obstructive Pulmonary Disease (COPD). The aim of this study was to identify the characteristics of frail patients with COPD to define a new phenotype called "COPD-frail." We conducted a cross-sectional study in a cohort of patients with stable COPD, classified as either frail, pre-frail, or non-frail. Sociodemographic, clinical, and biochemical variables were compared between the three groups of patients. The study included 127 patients, of which 31 were frail, 64 were pre-frail, and 32 non-frail. All subjects had FEV1/FVC below…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyphenotypeFrail ElderlyFrailty syndromefrailtyHospital Anxiety and Depression ScaleSeverity of Illness IndexFEV1/FVC ratioPulmonary Disease Chronic ObstructiveInternal medicineMedicineCOPDHumansAgedCOPD-frailCOPDFrailtybusiness.industrymedicine.diseaseObstructive lung diseaserespiratory tract diseasesCross-Sectional StudiesDyspneaPhenotypeCohortAnxietymedicine.symptombusinessBody mass indexhuman activitiesCOPD
researchProduct

Oxidative and nitrosative stress in the diaphragm of patients with COPD.

2007

COPD is associated with an increased load on the diaphragm. Since chronic muscle loading results in changes in antioxidant capacity and formation of reactive oxygen and reactive nitrogen species, we hypothesized that COPD has a similar effect on the diaphragm, which is related to the severity of COPD. Catalase activity was determined spectrophotometrically. Levels of 4-hydroxy-2-nonenal (HNE)-protein adducts and 3-nitrotyrosine (NT) formation were measured using western blotting. Levels of malondialdehyde (MDA) were assessed by high-performance liquid chromatography. We found that catalase activity was approximately 89% higher in the diaphragm of severe COPD patients (FEV1 37+/-5% predicted…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyrespiratory musclesNitrosationDiaphragmOxidative phosphorylationmedicine.disease_causeSeverity of Illness IndexNOLipid peroxidationPulmonary Disease Chronic Obstructivechemistry.chemical_compoundInternal medicineHumansCOPDMedicineReactive nitrogen speciesOriginal ResearchCOPDoxidantsbiologybusiness.industryHealth PolicyPublic Health Environmental and Occupational HealthGeneral MedicineMiddle Agedmedicine.diseaseMalondialdehydeDiaphragm (structural system)Surgeryrespiratory tract diseasesOxidative StressantioxidantsEndocrinologychemistryCatalasebiology.proteinbusinessOxidative stressInternational journal of chronic obstructive pulmonary disease
researchProduct